Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study

Zhaowei Meng, Jian Tan, Qing He, Mei Zhu, Xue Li, Jianping Zhang, Qiang Jia, Shen Wang, Guizhi Zhang, and Wei Zheng

1 Department of Nuclear Medicine, Tianjin Medical University General Hospital, Anshan Road No. 154, Heping District, Tianjin 300052, China
2 Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300052, China

Correspondence should be addressed to Zhaowei Meng; jamesmenciau@163.com and Jian Tan; tanposta@163.com

Received 27 June 2014; Revised 5 October 2014; Accepted 12 October 2014

Academic Editor: Myeong Soo Lee

Copyright © 2015 Zhaowei Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We aimed to compare effectiveness of Wenxin Keli (WK) and sotalol in assisting sinus rhythm (SR) restoration from paroxysmal atrial fibrillation (PAF) caused by hyperthyroidism, as well as in maintaining SR. We randomly prescribed WK (18 g tid) or sotalol (80 mg bid) to 91 or 89 patients. Since it was not ethical not to give patients antiarrhythmia drugs, no control group was set. Antithyroid drugs were given to 90 patients (45 in WK group, 45 in sotalol group); \(^{131}\text{I}\) was given to 90 patients (46 in WK group, 44 in sotalol group). Three months later, SR was obtained in 83/91 or 80/89 cases from WK or sotalol groups \((P = 0.762)\). By another analysis, SR was obtained in 86/90 or 77/90 cases from \(^{131}\text{I}\) or ATD groups \((P = 0.022)\). Then, we randomly assigned the successfully SR-reverted patients into three groups: WK, sotalol, and control (no antiarrhythmia drug was given) groups. After twelve-month follow-up, PAF recurrence happened in 1/54, 2/54, and 9/55 cases, respectively. Log-Rank test showed significant higher PAF recurrent rate in control patients than either treatment \((P = 0.06)\). We demonstrated the same efficacies of WK and sotalol to assist SR reversion from hyperthyroidism-caused PAF. We also showed that either drug could maintain SR in such patients.

1. Introduction

Atrial fibrillation is the most common cardiac rhythm disturbance, increasing in prevalence with age. By definition, atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation with consequent deterioration of atrial mechanical function [1–3]. Clinicians should distinguish a first-detected episode of atrial fibrillation, whether or not it is symptomatic or self-limited. Patients with atrial fibrillation have markedly reduced survival rate compared with subjects without atrial fibrillation. In paroxysmal atrial fibrillation (PAF), sudden repeated changes in rhythm cause symptoms which most patients find very debilitating. In addition, PAF carries an increasing risk of thromboembolic events, when compared with chronic atrial fibrillation [4, 5]. Therefore, the effective treatment and prevention of this kind of arrhythmia has important clinical significance [1–3, 6, 7]. Atrial fibrillation occurs in 10% to 25% of patients with hyperthyroidism, more commonly in men and elderly patients [2, 8, 9]. Mainstay treatment is restoration of euthyroid state, which can be accomplished by antithyroid drugs, \(^{131}\text{I}\), and surgery. Successful management of hyperthyroidism could result in restoration of sinus rhythm (SR) in up to two-thirds of patients [10]. Mechanism of hyperthyroidism-induced atrial fibrillation has been proposed [10–12]. It is generally agreed that shortening of action potential duration and effective refractory period play key roles in this electrophysiological abnormality.

Wenxin Keli (WK) is a pure Chinese herb medicine. It has been reported to be useful in the treatment of atrial fibrillation [13–15], ventricular arrhythmia [16, 17], myocardial infarction-induced arrhythmia, heart failure, Brugada syndrome [18], and so forth. WK extract is composed of 5
2.2. Definition. The diagnosis of PAF was made according to the American College of Cardiology Foundation/American Heart Association Task Force guideline definition; briefly, PAF had episodes that were generally less than 7 days (most less than 24 h), yet it was usually recurrent [1, 2].

2.3. Protocol. This study was designed as a prospective, open label, and randomized investigation. Generally, patients eligible for the study were allocated to one of the treatments using a computer generated random number algorithm. As reported [15], the clinical applications of WK against PAF include two aspects: restoration of SR from PAF and maintenance of SR afterwards. Therefore, we divided our study into two stages of sinus restoration and maintenance, in order to determine WK’s effects on these two aspects.

Initially, baseline demographic data were obtained from the subjects. Relevant symptoms, cardiac diagnoses, and medical history were noted. Physical examination, 24-hour ambulatory electrocardiograph and/or regular 12-lead electrocardiograph, and serum biochemical tests (including electrolytes and renal and liver function) were carried out. All electrocardiographic recordings were reviewed by at least two experienced observers.

In the first part of the study, we randomly prescribed WK (18g tid) or sotalol (80 mg bid) to 91 patients (49 males, 42 females) or 89 patients (49 males, 40 females), respectively. This part of the study compared the effectiveness of WK and sotalol to restore SR from PAF. In this investigation, it was not ethical not to give the patients any antiarrhythmia drugs. So, we did not design control; we just compared WK and sotalol. Antithyroid drugs (ATD) were given to 90 patients (45 in WK group, 45 in sotalol group), and $^{131}$I was also given to 90 patients (46 in WK group, 44 in sotalol group). Due to the similar ethical reason, no control group was set. ATD-treated patients were given methimazole (initial dose 30 mg per day). $^{131}$I therapeutic procedure was performed according to our protocol [19, 20]. Thyroid radioiodine uptake value was measured at 6, 24, 48, and 72 hours after an oral tracer dose uptake of $^{131}$I (about 74kBq) by a nuclear multifunctional instrument (MN-6300XT Apparatus, Technological University, China). Then $^{131}$I effective half-life ($T_{1/2 eff}$) and maximum uptake in thyroid were calculated. Thyroid ultrasonography was performed by using a color doppler ultrasound machine (GE Vingmed Ultrasound Vivid Five, Horten, Norway). Thyroid volume was calculated with the following formula: volume (cm$^3$) = (width × length × thickness of left lobe) + (width × length × thickness of right lobe). Thyroid weight (g) = 0.479 × volume (cm$^3$). Serum thyroid hormones were tested by an immunofluorometric assay, including free triiodothyronine (FT3, reference 3.50–6.50 pmol/L), free thyroxine (FT4, reference 11.50–23.50 pmol/L), and thyroid stimulating hormone (TSH, reference 0.20–5.00 μIU/mL). The therapeutic dose of $^{131}$I was calculated as the following formula [19, 20]: dose (37 MBq) = (thyroid weight (g) × absorption dose (Gy/g) × 0.67) / ($T_{1/2 eff}$ (days) × maximum uptake (%)). Absorption dose = 100 Gy/g thyroid tissue; 0.67 is a rectified factor. Participants visited our outpatient department every month. At each scheduled follow-up visit, physical examination and routine laboratory tests were done. And, at the end of the third month, ambulatory electrocardiograph and/or regular 12-lead electrocardiograph were repeated; all relevant symptoms were documented. Disappearing of PAF was defined as restoration of SR.

In the second part of the study, we randomly assigned the successfully SR-reverted patients into one of the following three groups: 54 cases were given WK (9 g tid), 54 cases were given sotalol (40 mg bid), and 55 cases served as control.
In this part of the study, the control patients did not take any antiarrhythmia drug. Since patients recruited at this stage had much better improved thyroid status, and all of them were in SR when entering this investigation, it was ethically approved by our Institutional Review Board not to give the control patients any antiarrhythmia drugs. If patients were still in hyperthyroidism status, appropriate dose of methimazole was given to maintain euthyroidism. If the patients were in posttherapeutic hypothyroidism status, appropriate dose of levothyroxine was given to maintain euthyroidism. For hypothyroid patients who had already restored SR, WK and sotalol were stopped. Participants were asked to visit our outpatient department every three months. At each scheduled or sometimes unscheduled follow-up visit, physical examination and routine laboratory tests were repeated. And, at the end of the twelfth month, ambulatory electrocardiograph and/or regular 12-lead electrocardiograph were done; all relevant symptoms were documented. Time-point of PAF recurrence, its frequency, and related symptoms were collected as well. Participant flow chart was presented in Figure 1 to illustrate the whole study process for better understanding.

2.4. Statistical Analysis. All data were presented as mean ± SD. Statistics were performed with SPSS 17.0 (SPSS Incorporated, IL, USA). Differences between two groups were analyzed by independent samples t-test. Differences between multiple groups were analyzed by one-way analysis of variance (ANOVA), and then least significant difference (LSD) test was used for multiple comparisons among the groups. \( \chi^2 \) test was adopted to determine case number changes of patients after different treatments. \( \chi^2 \) test was also used to check whether sex had a significant influence on the intergroup differences. Kaplan-Meier analysis by Log-Rank \( \chi^2 \) test was used to estimate the cumulative recurrent rate of PAF in different groups. \( P \) value not exceeding 0.05 was considered statistically significant.

3. Results

3.1. Sinus Rhythm Restoration by Different Therapies. First, baseline information revealed no significant differences of hyperthyroidism history, PAF history, or thyroid hormone levels between the groups (Table 1). Data in this investigation were analyzed by two ways. In the first analysis, three months after treatment of WK or sotalol, SR was obtained in 83/91 cases (91.209%) or 80/89 cases (89.888%); \( \chi^2 \) test showed no significant differences, indicating equal efficacies of the two drugs for assisting SR reversion (Table 2). Sex did not cause significant differences between the groups (Table 2). Thyroid hormones also demonstrated no differences before or after treatments (Table 3). In the second analysis, after treatment of \(^{131}\)I or ATD, SR was obtained in 86/90 cases or 77/90 cases; \( \chi^2 \) test showed significant differences, indicating better effects of \(^{131}\)I treatment (Table 4). Thyroid hormones displayed no differences before treatment, yet significant differences existed after treatment (Table 5). A typical case showing successful converted SR from PAF was presented (Figure 2).

3.2. Sinus Rhythm Maintenance by Different Therapies. Data in the second investigation were analyzed by two methods. First, at the end of twelve-month follow-up, recurrent PAF happened in 1/54 (1.852%), 2/54 (3.704%), and 9/55 (16.364%) cases in WK, sotalol, or control groups, respectively. We found no differences of thyroid hormones at any follow-up time-point among the groups (Table 6). However, \( \chi^2 \) test showed significant differences between WK and control groups and significant differences between sotalol and control groups, while there were no differences between WK and sotalol groups (Table 7). Second, Kaplan-Meier curves were drawn to determine the cumulative recurrent rate of PAF in different groups (Figure 3). Log-Rank test showed significant higher PAF recurrent rate in control patients compared with either treatment (\( \chi^2 = 10.229, P = 0.06 \)). Therefore, we proved that both WK and sotalol could successfully maintain SR.

3.3. Side Effects. Since there is always an inherent bitter taste in Chinese medicine, some patients would unadvisedly complain about the gastrointestinal discomfort or related symptoms after taking WK. Altogether, there were 10/91 cases (10.989%) in the first investigation and 6/54 (11.11%) in the second investigation who reported various degrees of nausea and dizziness after taking WK. However, all patients showed endurance and continued with the medication. For sotalol groups, the gastrointestinal discomfort was far less frequent; there were only 3/89 cases (3.371%) in the first investigation and 2/54 (3.704%) in the second investigation who reported mild stomach discomfort. However, after taking sotalol, 2/89 cases (2.247%) in the first investigation developed symptomatic bradycardia, whose PAF disappeared though. The problems completely dissolved after dose reduction from 80 mg bid to 40 mg bid for one patient and from 80 mg bid to 40 mg qd for the other patient. These two patients'
Figure 1: Participant flow chart. Initially, in the first stage of the study (a), 180 eligible hyperthyroidism patients with paroxysmal atrial fibrillation were randomized into either Wenxin Keli (91 cases) or sotalol (89 cases) treatment for sinus rhythm restoration. At the end of the first stage intervention, 83/91 cases and 80/89 cases were reverted to sinus rhythm, respectively. There were 8/91 cases and 9/89 cases who did not restore sinus rhythm. These 17 patients (still with atrial fibrillation) were not eligible for the second part of the study, and they were dropped out. In the second stage of the study (b), all sinus rhythm reverted patients (163 cases) were randomized into one of the following three groups: WK (54 cases), sotalol (54 cases), and control (55 cases) groups. The purpose is to observe drug's sinus rhythm maintenance effect. At the end of the second stage intervention, 1/54 cases, 2/54 cases, and 9/55 cases had recurrent paroxysmal atrial fibrillation, respectively.

Table 2: Case number distribution of patients after WK* or sotalol treatments in the first investigation.

| Groups (case number) | Total number | Male | SR* restored number | Total number | Female | SR* restored number |
|----------------------|--------------|------|---------------------|--------------|--------|---------------------|
| WK* treatment (91 cases) | 49           | 49   | 45                  | 42           | 42     | 38                  |
| Sotalol treatment (89 cases) | 49           | 49   | 44                  | 40           | 40     | 36                  |

χ² value (P value), **<sub>(WK):(sotalol)</sub> = 0.092 (0.762)

χ² value (P value), **<sub>(male):(female)</sub> = 0.017 (0.896)

*WK: Wenxin Keli; SR: sinus rhythm; ** analyzed by χ² test.
Heart rhythm maintained SR during the rest of the study. WK showed no bradycardia side effect. No other unwanted incidences were recorded.

4. Discussion

The risk of developing atrial fibrillation in patients with hyperthyroidism is approximately 6-fold of the euthyroidism population, which aggravates the overall conditions of such patients [9]. Successful treatment of hyperthyroidism with either $^{131}$I or ATD is associated with a reversion to SR in a majority of patients [10, 21, 22]. However, pharmacological management of atrial fibrillation in patients with hyperthyroidism is still an issue lacking in comprehensive analysis. In general, rate control is very important to reduce the mortality rate of patients with atrial fibrillation [6, 7]. Selective or nonselective β-blockers can provide rapid symptom relief by reducing the ventricular rate, but these agents are unlikely to convert PAF to SR. Pharmacotherapy of atrial fibrillation has an advantage over electrical cardioversion and the catheter ablation methods, because it can be used on an outpatient basis [23]. However, the optimal pharmacological means to restore and maintain SR in patients with hyperthyroidism-caused atrial fibrillation remains controversial.

WK is identified as a novel drug against atrial fibrillation. Its mechanism has been elucidated recently. Burashnikov and colleagues [13] have implemented an isolated canine perfused right atrial preparation and recorded atrial and ventricular transmembrane action potentials and pseudoelectrograms before and after intracoronary perfusion of various concentrations of WK. Interestingly, WK produced effects more noticeable in atrial tissue than in ventricular tissue, as it caused action potential duration shortening and prolongation of effective refractory periods in an atrial-selective manner. In addition, WK produced a greater reduction in the maximum rate of rise of the action potential upstroke and a larger increase in the diastolic threshold for excitation in atrial cells, suggestive of sodium-channel current blockade. This was confirmed in HEK293 cells expressing the sodium ion channel protein SCN5A, in which WK decreased the peak sodium-channel current, in both dose-dependent and use-dependent fashions. Finally, antiarrhythmic properties of WK were illustrated by the prolongation of the P-wave duration and both the prevention and termination of acetylcholine-mediated atrial fibrillation. The above mechanism of WK acts directly against the electrophysiological changes in hyperthyroidism-induced atrial fibrillation [10–12].

Contrary to the relatively new discovery of the MK mechanisms, traditional Chinese medicines were first documented about 2500 years ago by Confucian scholars and are now still being used by tens of millions in China as well as around the world [14, 24, 25]. Clinical evidence of WK is based on results of clinical trials being carried out in Chinese hospitals for years. These studies have shown that WK can significantly improve heart palpitations, chest tightness, shortness of breath, fatigue, insomnia, and other symptoms of atrial fibrillation [15]. Currently, WK monotherapy or combined therapy with antiarrhythmic drugs has been recommended as an effective method for atrial fibrillation in China. In fact, WK is the first Chinese-developed antiarrhythmic medicine to be approved by the Chinese state. Besides antiarrhythmic property, clinical trials have also confirmed that WK can increase coronary blood flow, reduce myocardial oxygen consumption, enhance myocardial compliance, improve myocardial hypoxia tolerance, relieve anterior and posterior cardiac

Table 3: Comparisons of thyroid hormones in patients before and after WK* or sotalol treatments in the first investigation.

| Groups (case number) | Male | Female | Male | Female |
|----------------------|------|--------|------|--------|
| FT3* (pmol/L)        | 24.613 ± 5.059 | 21.447 ± 11.727 | 24.405 ± 5.006 | 21.655 ± 10.612 |
| FT4* (pmol/L)        | 118.697 ± 29.213 | 6.210 ± 10.002 | 116.132 ± 28.266 | 5.059 ± 24.405 |
| TSH* (µIU/mL)        | 0.007 ± 0.010 | 0.009 ± 0.147 | 0.009 ± 0.147 | 0.009 ± 0.147 |

*WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; **analyzed by independent samples t-test.

Table 4: Case number distribution of patients after $^{131}$I or ATD* treatments in the first investigation.

| Groups (case number) | Total number | SR restored number | Male | Female |
|----------------------|--------------|--------------------|------|--------|
| $^{131}$I treatment (90 cases) | 49 | 47 | 41 | 39 |
| ATD* treatment (90 cases) | 49 | 42 | 41 | 35 |

$\chi^2$ value (P value)$_{\text{(ATD)}}$ ** | 5.262 (0.022) |

$\chi^2$ value (P value)$_{\text{(female)}}$ ** | 0.017 (0.896) |

*ATD: antithyroid drugs; SR: sinus rhythm; **analyzed by $\chi^2$ test.
Table 5: Comparisons of thyroid hormones in patients before and after $^{131}$I or ATD* treatments in the first investigation.

|                      | Before treatments $^{131}$I treatment (90 cases) | ATD* treatment (90 cases) | t value ($P$ value)** |
|----------------------|-------------------------------------------------|---------------------------|-----------------------|
| FT3* (pmol/L)        | 24.056 ± 5.321                                  | 24.964 ± 4.685            | 1.215 (0.226)         |
| FT4* (pmol/L)        | 117.633 ± 29.225                                | 117.225 ± 28.322          | −0.095 (0.924)        |
| TSH* (μIU/mL)        | 0.007 ± 0.011                                   | 0.009 ± 0.014             | 0.757 (0.450)         |

Three months after treatments

|                      | Before treatments $^{131}$I treatment (90 cases) | ATD* treatment (90 cases) | t value ($P$ value)** |
|----------------------|-------------------------------------------------|---------------------------|-----------------------|
| FT3* (pmol/L)        | 5.837 ± 2.830                                   | 7.252 ± 4.330             | 2.595 (0.010)         |
| FT4* (pmol/L)        | 19.378 ± 8.292                                  | 23.722 ± 13.120           | 2.655 (0.009)         |
| TSH* (μIU/mL)        | 6.427 ± 9.702                                   | 5.539 ± 9.237             | −0.629 (0.530)        |

*ATD: antithyroid drugs, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; **analyzed by independent samples t-test.

Table 6: Comparisons of thyroid hormones at any follow-up time-points in the second investigation.

|                      | WK* treatment (54 cases) | Sotalol treatment (54 cases) | Control (55 cases) | F value ($P$ value)** |
|----------------------|--------------------------|-------------------------------|-------------------|-----------------------|
| FT3* (pmol/L)        | 5.532 ± 2.372            | 5.752 ± 2.608                 | 5.680 ± 2.486     | 0.110 (0.896)         |
| FT4* (pmol/L)        | 18.469 ± 7.182           | 19.351 ± 7.577               | 19.046 ± 7.576    | 0.195 (0.982)         |
| TSH* (μIU/mL)        | 7.126 ± 10.449           | 5.859 ± 8.668                | 6.832 ± 10.110    | 0.249 (0.780)         |

Three months

|                      | WK* treatment (54 cases) | Sotalol treatment (54 cases) | Control (55 cases) | F value ($P$ value)** |
|----------------------|--------------------------|-------------------------------|-------------------|-----------------------|
| FT3* (pmol/L)        | 5.035 ± 0.934            | 5.129 ± 0.908                 | 5.098 ± 0.965     | 0.140 (0.870)         |
| FT4* (pmol/L)        | 15.664 ± 3.112           | 16.061 ± 3.336               | 15.994 ± 3.465    | 0.222 (0.801)         |
| TSH* (μIU/mL)        | 4.683 ± 4.211            | 4.083 ± 3.456                | 4.352 ± 3.885     | 0.326 (0.722)         |

Six months

|                      | WK* treatment (54 cases) | Sotalol treatment (54 cases) | Control (55 cases) | F value ($P$ value)** |
|----------------------|--------------------------|-------------------------------|-------------------|-----------------------|
| FT3* (pmol/L)        | 5.257 ± 0.930            | 5.373 ± 0.915                 | 5.381 ± 1.057     | 0.277 (0.758)         |
| FT4* (pmol/L)        | 16.446 ± 3.339           | 16.916 ± 3.727               | 16.955 ± 4.014    | 0.317 (0.729)         |
| TSH* (μIU/mL)        | 4.032 ± 3.492            | 3.567 ± 2.885                | 3.756 ± 3.202     | 0.288 (0.750)         |

Nine months

|                      | WK* treatment (54 cases) | Sotalol treatment (54 cases) | Control (55 cases) | F value ($P$ value)** |
|----------------------|--------------------------|-------------------------------|-------------------|-----------------------|
| FT3* (pmol/L)        | 5.367 ± 0.975            | 5.458 ± 0.958                 | 5.590 ± 1.328     | 0.566 (0.569)         |
| FT4* (pmol/L)        | 17.184 ± 3.208           | 17.760 ± 4.131               | 18.084 ± 4.833    | 0.668 (0.514)         |
| TSH* (μIU/mL)        | 2.912 ± 1.730            | 2.701 ± 1.666                | 2.785 ± 1.719     | 0.211 (0.810)         |

Twelve months

|                      | WK* treatment (54 cases) | Sotalol treatment (54 cases) | Control (55 cases) | F value ($P$ value)** |
|----------------------|--------------------------|-------------------------------|-------------------|-----------------------|
| FT3* (pmol/L)        | 5.562 ± 0.969            | 5.740 ± 1.302                 | 5.874 ± 1.406     | 0.866 (0.422)         |
| FT4* (pmol/L)        | 17.830 ± 3.485           | 18.532 ± 5.113               | 18.901 ± 5.388    | 0.716 (0.490)         |
| TSH* (μIU/mL)        | 2.519 ± 1.420            | 2.388 ± 1.423                | 2.409 ± 1.488     | 0.129 (0.879)         |

*WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; **analyzed by one-way analysis of variance and least significant difference test.

Table 7: Cumulative recurrent PAF* at the end of follow-up in the second investigation.

| Groups (case number) | Male | Female | $\chi^2$ value ($P$ value)** |
|----------------------|------|--------|------------------------------|
| WK* treatment (54 cases) | 27   | 27     | 6.886 (0.009)                |
| Sotalol treatment (54 cases) | 27   | 27     | 4.813 (0.028)                |
| Control (55 cases) | 35   | 20     | 0.343 (0.558)                |

*WK: Wenxin Keli; PAF: paroxysmal atrial fibrillation; **analyzed by $\chi^2$ test.
Evidence-Based Complementary and Alternative Medicine

Figure 2: A typical case of successful sinus rhythm restoration from paroxysmal atrial fibrillation. A 64-year-old male patient was diagnosed with Graves’ disease for eight years. He had paroxysmal atrial fibrillation for three years (a). He was given 6 mCi of $^{131}$I for the treatment of Graves’ disease. And Wenxin Keli (18 g tid) was prescribed during and after the $^{131}$I treatment. Baseline free triiodothyronine, free thyroxine, and thyroid stimulating hormone were 21.46 pmol/L, 104.8 pmol/L, and 0.011 μIU/mL, respectively. One month later, when sinus rhythm was restored (b), free triiodothyronine, free thyroxine, and thyroid stimulating hormone were 3.35 pmol/L, 12.89 pmol/L, and 4.52 μIU/mL, respectively. After entering the second investigation, Wenxin Keli (9 g tid) was prescribed during the follow-up. His thyroid function maintained normal level, and his heart rhythm maintained sinus rhythm during the rest of the study.

Figure 3: The cumulative recurrent rate of paroxysmal atrial fibrillation during the follow-up in different groups. In the second part of the study, we randomly assigned the successfully sinus rhythm reverted patients into one of the following three groups: 54 cases were given Wenxin Keli (9 g tid), 54 cases were given sotalol (40 mg bid), and 55 cases served as control. Kaplan-Meier analysis by Log-Rank $\chi^2$ test was used to determine the cumulative recurrent rate of paroxysmal atrial fibrillation in different groups during the one-year-long follow-up. Vertical axe was PAF recurrence free rate and horizontal axe was the follow-up time (WK = Wenxin Keli, PAF = paroxysmal atrial fibrillation).

loadings, and reduce myocardial tissue damage in patients with high blood pressure. These clinical evidences are in accordance with WK’s basic mechanistic research findings recently [13, 16–18].

In the current investigation, we provided the first clinical evidence of WK as well as sotalol on the management of hyperthyroidism-induced PAF in two aspects. First, the drugs could assist SR reversion from PAF caused by hyperthyroidism. Second, the drugs could maintain SR afterwards. The second application seemed more important, since the first application was very dependent on the degree of thyroid hormone reduction. We showed that there were nearly the same efficacies of both WK and sotalol to assist SR restoration. However, $^{131}$I was much more effective for hyperthyroidism management and thereafter to gain better SR reversion. We believed that this was largely due to better therapeutic results of $^{131}$I to control thyroid hormones (Tables 4 and 5). In the latter investigation, we showed that both WK and sotalol could maintain SR with equal abilities in our cohort, who have already gained SR after treatments. The cumulative recurrent rate was significantly lower in the drug-treated patients than in the control cases (Figure 3). Our study proved the usefulness and effectiveness of WK as well as sotalol on the long-term maintenance management of such patients, which is indeed very important for clinical purposes.

Although WK’s effect on hyperthyroidism-related atrial fibrillation has never been reported before, WK’s anti-atrial-fibrillation ability is not new discovery. All of WK’s clinical studies are published in Chinese language so far; however, after considering their relevancy to the current study, further comments are deserved. Chen and colleagues [15] compiled and evaluated all available randomized controlled trials regarding WK’s therapeuticeffects against PAF (complicated with diseases other than hyperthyroidism) according to the PRISMA systematic review standard. There were nine trials analyzing therapeutic effectiveness of WK alone or combined with Western medicine, compared with no medicine or Western medicine alone, in patients with PAF [26–34]. Most of the trials used amiodarone as the Western medicine, which cannot be used for hyperthyroidism-related atrial fibrillation. These trials were not homogeneous, requiring the use of the random effects model for statistical analysis. Meta-analysis results demonstrated a significant difference between the two therapeutic groups (the WK combination therapy was much better). Seven trials used the maintenance rate of SR at six months following treatment as an outcome measurement [33–39]. These seven trials compared the combination of WK plus Western medicine with Western medicine alone (mostly
amiodarone). These trials were homogeneous, requiring the use of the fixed effects model for statistical analysis. The rate of maintenance of SR in the former group was greater than the latter group. Meta-analysis results showed that there was a significant beneficial effect in the WK combination regimens compared with the Western medicine monotherapy. The above literature is in conformity with our findings in that WK is an effective drug for the management of PAF, not only for initial SR reversion therapy but also for the long-term maintenance therapy.

In conclusion, we demonstrated the same efficacies of WK and sotalol to assist SR reversion from hyperthyroidism-related PAF. I was better to control thyroid hormone and to gain SR reversion. We also showed that both WK and sotalol could maintain SR with equal abilities in those PAF hyperthyroidism patients who had already gained SR after treatments. Therefore, WK is a useful drug that should be advocated in the initial treatment of PAF caused by hyperthyroidism, as well as in the follow-up management strategy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This investigation was supported by the National Key Clinical Specialty Project (awarded to the Departments of Nuclear Medicine and Radiology). This study was also supported by Tianjin Medical University New Century Excellent Talent Program, Young and Middle-aged Innovative Talent Training Program from Tianjin Education Committee, and Talent Fostering Program (the 131 Project) from Tianjin Human Resources and Social Security Bureau (awarded to Zhaowei Meng). The authors wish to thank Buchang Pharma Co. Ltd. for providing the drug of Wenxin Keli.

References

[1] L. S. Wann, A. B. Curtis, C. T. January et al., “2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 57, no. 2, pp. 223–242, 2011.

[2] V. Fuster, L. E. Rydén, D. S. Cannom et al., “2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 57, no. 11, pp. e101–e198, 2011.

[3] G. Y. Lip and H.-F. Tse, “Management of atrial fibrillation,” The Lancet, vol. 370, no. 9587, pp. 604–618, 2007.

[4] R. P. Steeds, A. S. Birchall, M. Smith, and K. S. Channer, “An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation,” Heart, vol. 82, no. 2, pp. 170–175, 1999.

[5] T. Sanna and V. Di Lazzaro, “Thromboembolic risk management in paroxysmal atrial fibrillation after brain haemorrhage,” International Journal of Stroke, vol. 6, no. 1, pp. 92–93, 2011.

[6] M. E. Cain and A. B. Curtis, “Rhythm control in atrial fibrillation—one setback after another,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2725–2727, 2008.

[7] D. Roy, M. Talajic, S. Nattel et al., “Rhythm control versus rate control for atrial fibrillation and heart failure,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2667–2677, 2008.

[8] C. T. Savin, A. Geller, P. A. Wolf et al., “Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons,” The New England Journal of Medicine, vol. 331, no. 19, pp. 1249–1252, 1994.

[9] I. Klein and S. Danzi, “Thyroid disease and the heart,” Circulation, vol. 116, no. 15, pp. 1725–1735, 2007.

[10] A. Bielecka-Dabrowa, D. P. Mikhailidis, J. Rysz, and M. Banach, “The mechanisms of atrial fibrillation in hyperthyroidism,” Thyroid Research, vol. 2, no. 1, article 4, 2009.

[11] K. Wustmann, J. P. Kucera, A. Zanchi et al., “Activation of electrical triggers of atrial fibrillation in hyperthyroidism,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 6, pp. 2104–2108, 2008.

[12] N. Komiya, S. Isomoto, K. Nakao, M. Hayano, and K. Yano, “Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism,” Clinical Endocrinology, vol. 56, no. 1, pp. 39–44, 2002.

[13] A. Burashnikov, A. Petroski, D. Hu, H. Barajas-Martinez, and C. Antzelevitch, “Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation,” Heart Rhythm, vol. 9, no. 1, pp. 125–131, 2012.

[14] J. Kalifa and U. M. R. Avula, “The Chinese herb extract Wenxin Keli: atrial selectivity from the Far East,” Heart Rhythm, vol. 9, no. 1, pp. 132–133, 2012.

[15] Y. Chen, S. Nie, H. Gao et al., “The effects of Wenxin Keli on P-wave dispersion and maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 245958, 9 pages, 2013.

[16] X. Wang, Y. Gu, T. Wang, and C. Huang, “Wenxin Keli attenuates ischemia-induced ventricular arrhythmias in rats: involvement of L-type calcium and transient outward potassium currents,” Molecular Medicine Reports, vol. 7, no. 2, pp. 519–524, 2013.

[17] X. Xue, D. Guo, H. Sun et al., “Wenxin Keli suppresses ventricular triggered arrhythmias via selective inhibition of late sodium current,” Pacing and Clinical Electrophysiology, vol. 36, no. 6, pp. 732–740, 2013.

[18] Y. Minoura, B. K. Panama, V. V. Nesterenko et al., “Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome,” Heart Rhythm, vol. 10, no. 7, pp. 1054–1062, 2013.

[19] R. F. Wang, J. Tan, G. Z. Zhang, Z. W. Meng, and W. Zheng, “A comparative study of influential factors correlating with early and late hypothyroidism after 131I therapy for graves’ disease,” Chinese Medical Journal, vol. 123, no. 12, pp. 1528–1532, 2010.
[20] W. Zheng, T. Jian, Z. Guizhi, M. Zhaowei, and W. Renfei, "Analysis of 131I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study," Nuclear Medicine Communications, vol. 33, no. 1, pp. 97–101, 2012.

[21] H. Nakazawa, D. A. Lythall, J. Noh et al., "Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation," European Heart Journal, vol. 21, no. 4, pp. 327–333, 2000.

[22] Z. H. Zhou, L. L. Ma, and L. X. Wang, "Risk factors for persistent atrial fibrillation following successful hyperthyroidism treatment with radioiodine therapy," Internal Medicine, vol. 50, no. 24, pp. 2947–2951, 2011.

[23] Y. Kunii, T. Uruno, M. Matsumoto et al., "Pharmacological conversion of atrial fibrillation in the patients of Graves' disease," Tokai Journal of Experimental and Clinical Medicine, vol. 37, no. 4, pp. 107–112, 2012.

[24] E. Chan, M. Tan, J. Xin, S. Sudarsanam, and D. E. Johnson, "Interactions between traditional Chinese medicines and Western therapeutics," Current Opinion in Drug Discovery & Development, vol. 13, no. 1, pp. 50–65, 2010.

[25] X. J. Li and H. Y. Zhang, "Western healers in traditional Chinese medicine," EMBO Reports, vol. 9, no. 2, pp. 112–113, 2008.

[26] J. D. Cheng, "Clinical observation of Wenxin Keli for the treatment of paroxysmal atrial fibrillation," Chinese Journal of Information on Traditional Chinese Medicine, vol. 14, no. 8, pp. 55–56, 2007.

[27] Y. Dong, L. F. Xing, B. M. Li, and C. J. Tong, "Effect of Wenxin particle combine with fluvastatin on atrial remodelling in essential hypertension patients with atrial fibrillation," Chinese Journal of Difficult and Complicated Cases, vol. 9, no. 8, pp. 566–568, 2010.

[28] S. R. Jin, "The effect of Wenxin Keli on P wave dispersion and the treatment for the paroxysmal atrial fibrillation," Chinese Journal of Modern Drug Application, vol. 5, no. 12, pp. 92–93, 2011.

[29] N. Lv, D. Lin, and P. Lin, "Wenxin granule and low dose amiodarone in treating 60 cases of senile paroxysmal atrial fibrillation," Fujian Journal of Traditional Chinese Medicine, vol. 41, no. 3, pp. 7–8, 2010.

[30] C. J. Zhang, "Effect of Wenxin granule treatment for paroxysmal atrial fibrillation patients," Practical Pharmacy and Clinical Remedies, vol. 15, no. 11, pp. 737–739, 2012.

[31] M. L. Zhang, S. X. Jing, and H. Y. Zhang, "The effect of Buchangwenxin particle on dispersion of P wave in elderly patients with diastolic cardiac dysfunction and paroxysmal atrial fibrillation," Chinese Journal of Primary Medicine and Pharmacy, vol. 18, no. 20, pp. 2756–2758, 2011.

[32] Z. M. Zhang, P. Bai, and J. Z. Lin, "Wenxin Keli combined with ethylamine iodine skin ketone in treating senile hypertension paroxysmal atrial fibrillation," Chinese Journal of Hypertension, vol. 16, no. 12, pp. 1134–1135, 2008.

[33] J. L. Lu, Y. Dong, and L. F. Xing, "The maintenance of sinus rhythm in patients with elderly hypertensive paroxysmal atrial fibrillation and the intervention of Wenxin Keli combined with fluvastatin," Hebei Medical Journal, vol. 32, no. 24, pp. 3483–3484, 2010.

[34] Y.-J. Yan, Y.-M. Zhang, Y. Lu, S.-Y. Wang, and H.-D. Cui, "Effect of Wenxin-Keli combined with amiodarone on dispersion of P wave and C-reactive protein in patients with paroxysmal atrial fibrillation," Chinese Journal of New Drugs, vol. 20, no. 15, pp. 1432–1434, 2011.

[35] B. Gao, "Clinical observation of Wenxin Keli combined with valsartan on the maintenance of sinus rhythm in patients with hypertension with paroxysmal atrial fibrillation," Chinese Community Doctors, vol. 14, no. 7, p. 54, 2012.

[36] F. C. Li, J. J. Tong, W. Hao, and Z. Ma, "The effect of Wenxin Keli combined with amiodarone for the treatment of paroxysmal atrial fibrillation in 32 cases," Shanxi Journal of Traditional Chinese Medicine, vol. 29, no. 7, pp. 839–840, 2008.

[37] P.-Y. Xie and S.-H. Shen, "Effect of combination of Chinese and Western medicines on sinus rhythm maintenance in patients with auricular fibrillation after conversion," Chinese Journal of Integrated Traditional and Western Medicine, vol. 26, no. 7, pp. 644–646, 2006.

[38] S. Z. Xu, "The study of prevention and curative effect of the Valsartan and Wenxin Keli on the paroxysmal atrial fibrillation," Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 8, no. 4, pp. 6–7, 2008.

[39] Q. H. Zheng and X. B. Zhang, "The effect of Wenxin Keli combined with amiodarone on the maintenance of sinus rhythm and serum MMP-9 in patients with paroxysmal atrial fibrillation," Guiding Journal of Traditional Chinese Medicine and Pharmacology, vol. 19, no. 2, pp. 36–37, 2013.